close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Immunis, Inc.

News headline image
Immunis Named Semifinalist in National Academy of Medicine’s $1.5 Million Healthy Longevity Global Competition Grand Prize
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Licenses Treatment Candidate for Dyskinesia Associated with Parkinson’s Disease
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Publishes Research Showing Body Fat Loss and Reversal of Liver Steatosis and Fibrosis, While Increasing Lean Muscle Mass, in Aged Models
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Named Among Top 25 Biotech & Life Sciences Companies for 2025 by The Healthcare Technology Report
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Named a Semifinalist in the $101 Million XPRIZE Healthspan Competition
From Immunis, Inc.
Via Business Wire
News headline image
Immunis’ Treats its First Patients for Sarcopenic Obesity
From Immunis, Inc.
Via Business Wire
News headline image
FDA Grants Clearance for Immunis’ Phase II Sarcopenic Obesity Trial
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Closes $25 Million Series A-1 Financing Round
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Partners with Springbok Analytics to Assess Clinical Efficacy of IMMUNA in Reversing Sarcopenia
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Initiates Non-Terminal Preclinical Studies to Address Canine Muscle Atrophy
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Appoints Dr. Christina Weng to its Advisory Board
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead is an Invited Speaker at the 2024 Brain Trust Conference
From Immunis, Inc.
Via Business Wire
News headline image
“The Time is Now” to Maximize Human Healthspan: A Discussion with Peter Diamandis, Hans Keirstead, Daniel Kraft and Jane Metcalfe
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead to Speak at the Longevity Investors Lunch in Davos
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead to Present at the 2024 Biotech Showcase
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead is Honored As One of OCBJ’s OC500
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Wins Two BASA Biotech Awards: “Best Small Business” and “Best Entrepreneur”
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany
From Immunis, Inc.
Via Business Wire
News headline image
Immunis is a Finalist for Best of America Small Business Awards – Vote for Us!!!
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chief Business Officer Mark Cabato to Deliver Keynote at the Drug Discovery Strategic Summit
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead to Present at Innovative Therapies Days in France
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Welcomes UC Berkeley Professor Irina Conboy to the Scientific Advisory Board
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead to Present at the Festival of Biologics in Basel
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Chairman Dr. Hans Keirstead to Present at Advanced Therapies in Portugal
From Immunis, Inc.
Via Business Wire
News headline image
Immunis is a Finalist for the High Tech Award for “Best Emerging Technology Company”
From Immunis, Inc.
Via Business Wire
News headline image
Immunis’ Phase 1/2a Clinical Trial Approved by Data Safety and Monitoring Board to Proceed with Dose Escalation
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Nominated for Prix Galien Award for “Best Startup”
From Immunis, Inc.
Via Business Wire
News headline image
Immunis Releases Article Highlighting the Potential of Cell Secretome Therapies in Addressing Immune and Age-Related Diseases
From Immunis, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.